Thalidomide apology insulting, campaigners say

Bronze statue symbolizing a child born without limbs because of thalidomide The bronze statue of a child born with thalidomide symptoms is on display in Stolberg, Germany

Related Stories

The company which invented thalidomide has "insulted" those affected by the drug by issuing an "insincere" apology, campaigners have said.

The drug, sold in the 1950s as a cure for morning sickness, was linked to birth defects and withdrawn in 1961.

German-based Gruenenthal has issued its first apology in 50 years, but said the drug's possible side-effects "could not be detected" before it was marketed.

But the UK's Thalidomide Trust said any apology should also admit wrongdoing.

Nick Dobrik, a member of the trust's national advisory council, said it "should be an unreserved apology, not a conditional apology".

Within months of thalidomide first going on sale in Germany, doctors were writing to Gruenenthal asking about side effects that were appearing in their patients.

The company's stock response was to say it was not aware of side-effects and that these must be down to the individual patient.

The company muffled the alarm bells - its apology now is next to worthless. It changes nothing about the company being negligent in putting the drug on the market.

Gruenenthal also tried, and almost succeeded, in dragging the legal process past the German statute of limitations to escape responsibility.

Almost everything that Gruenenthal has done relating to thalidomide has been absolutely disgraceful.

"We feel that a sincere and genuine apology is one which actually admits wrongdoing. The company has not done that and has really insulted the thalidomiders."


Martin Johnson, the trust's director, told the BBC that the news that the manufacturers were starting to acknowledge responsibility was welcome but they were still trying to perpetuate the myth that no-one could have known of the harm the drug could cause when there was, he said, much evidence that they did know.

And Freddie Astbury, president of Thalidomide UK, said: "It's taken a long time for them to apologise. There are a lot of people damaged by thalidomide struggling with health problems in the UK and around the world.

"So we welcome the apology, but how far do they want to go? It's no good apologising if they won't open discussions on compensation. They've got to seriously consider financial compensation for these people."

By the time the drug was pulled from the market, more than 10,000 babies worldwide had been born with a range of disabilities caused by the drug.

This included shortened arms and legs, blindness, deafness, heart problems and brain damage.

There are between 5,000 and 6,000 sufferers still alive. Thalidomide UK says there are 458 people in the UK who were affected by the drug, but that for every thalidomide baby that lived there were 10 that died.

Harald Stock, Gruenenthal's chief executive, issued his company's apology at the unveiling of a bronze statue symbolising a child born without limbs because of thalidomide.

"We ask for forgiveness that for nearly 50 years we didn't find a way of reaching out to you from human being to human being," he said at a ceremony in the western German city of Stolberg, where the firm is based.

"We ask that you regard our long silence as a sign of the shock that your fate caused in us."

Thalidomide timeline

  • 1953: Drug created in Germany by the Gruenenthal Group
  • 1958: Thalidomide is first licensed for use in the UK
  • 1961: Australian doctor William McBride reports an increase in deformed babies being born at his hospital to mothers who had taken thalidomide
  • Drug is withdrawn later that year
  • 1968: UK manufacturers Distillers Biochemicals Limited (now Diageo) reaches compensation settlement following a legal battle by affected families
  • 2005: Diageo doubles its compensation payouts from £2.8m to about £6.5m a year
  • 2008: The drug is approved for the treatment of multiple myeloma - bone marrow cancer - by the European Medicines Agency
  • 2009: UK government agrees a £20m grant, to be paid to the Thalidomide Trust over three years
  • 2010: UK health minister Mike O'Brien makes a formal apology to thalidomide survivors on behalf of the government

Mr Stock said the company regretted that the potential for thalidomide to affect the development of foetuses "could not be detected by the tests that we and others carried out before it was marketed".

Class action

BBC science correspondent for the Today programme, Tom Feilden, said one of the main issues was what Gruenenthal knew about the drug's side effects, when it knew about them and whether the company could have acted sooner in withdrawing it from the market.

Some compensation has been paid, particularly by thalidomide's British distributor.

Gruenenthal itself has previously paid compensation to survivors of the drug, many in Germany, and has voiced regret over the issue - but has not admitted liability.

In the early 1970s, it agreed to pay 100m Deutschmarks (£40m) into an official fund for German thalidomide survivors and was given permanent legal indemnity by the German government.

Since the original fund money ran out, continuing compensation payments have been made by the government. In 2009 the company added a further 50m euro (£39.6m) one-off endowment.

Compensation claims are still outstanding, including one key class action in Australia, which saw thalidomide survivors win the right to have their case for compensation heard there.

The drug is still used today under strict controls to treat some bone marrow cancer patients.


More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites


This entry is now closed for comments

Jump to comments pagination
  • rate this

    Comment number 219.

    When a corporate machine says sorry, is it anything more than another way to play the market ?

    Unfortunately what it indicates is the utter heartlessness of this mechanical world; where chemical pills are supposed to make you happy, and a recording on the phone tells you how valued you are.

    Reminds me of Blair apologising for something that happened 150 years ago !

    It's all quite ugly.

  • rate this

    Comment number 218.

    He should also apologise for taking so long to apologise. If the apologist & his company didn't know at the start this drug had issues then they certainly knew soon after. Not to know drugs had the horrible side affects that this one had before releasing them onto the market is to be blatantly irresponsible. Now that he has given an apology, he should concider his next step to pay compensation!

  • rate this

    Comment number 217.

    Although I can appreciate the anger and frustration when it has taken so long for the company to issue an apology, sadly the response they are getting can only encourage other drug companies to stay silent forever..

    It might have been VASTLY more productive to accept the apology and work on the basis of "so now lets talk compensation" rather than just make them regret breaking their silence.

  • rate this

    Comment number 201.

    I think I agree with the majority here:

    The UK should be compensated by this company. It has cost the NHS and tax payers untold millions to support those who were damaged by this drug; the UK treasury should get every penny back.

  • rate this

    Comment number 196.

    Better late than never definitely doesnt apply in this case.Maybe they should have just stayed silent after all if you dont have anything good to say. This is another one of those wonder somethings from the fifties that turned out to do more harm than good. So much for a golden age.


Comments 5 of 7


More Health stories


Features & Analysis

BBC Future

(Getty Images)

What it’s really like to die

The seven experiences you face at the end


  • Kinetic sculpture violinClick Watch

    The "kinetic sculpture" that can replicate digital files and play them on a violin

Try our new site and tell us what you think. Learn more
Take me there

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.